Date: _ April 3, 2	022
Your Name:	Ying Zhao
<b>Manuscript Title:</b>	Upregulation of FOXO1 contributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>	
Manuscript numb	per (if known): ATM-21-5380-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China , No. 31871156	Payment for experimental items, reagents, etc.
	medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China , No. 32171124	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.81672266	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.82072209	Payment for experimental items, reagents, etc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	<b>X</b> _None	

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:	Mar 31. 2022	
Your Name:	Hui Zhang	
Manuscript Title:	<b>Upregulation of FOX</b>	O1 contributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>		
Manuscript numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China , No. 31871156	Payment for experimental items, reagents, etc.
	medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China , No. 32171124	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.81672266	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.82072209	Payment for experimental items, reagents, etc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X _None	

3	Royalties or licenses	XNone	
4	Consulting fees	X _None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<b>X</b> _None	
6	Payment for expert testimony	X _None	
7	Support for attending meetings and/or travel	<b>X</b> _None	
8	Patents planned, issued or pending	X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X _None	
11	Stock or stock options	X _None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	X _None	

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

### ICMJE DISCLOSURE FORM

Date:	Mar 31. 2022	
Your Name:	Shuli Zhang	
Manuscript Title:	<b>Upregulation of FOXO1</b>	contributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>		
Manuscript numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China , No. 31871156	Payment for experimental items, reagents, etc.
	medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China , No. 32171124	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.81672266	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.82072209	Payment for experimental items, reagents, etc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> _None	

3	Royalties or licenses	XNone
4	Consulting fees	XNone
_		
5	Payment or honoraria for	X_None
	lectures, presentations, speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	<b>X</b> _None
	testimony	
7	Support for attending meetings and/or travel	X _None
	-	
8	Patents planned, issued or	X _None
	pending	
_		
9	Participation on a Data	X _None
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	V Name
10	in other board, society,	XNone
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	X_None
12	Receipt of equipment,	XNone
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

### ICMJE DISCLOSURE FORM

Date:	Mar 31. 2022	
Your Name:	Juan Wei	
Manuscript Title:	<b>Upregulation of FOXO</b>	1 contributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>		
Manuscript numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China , No. 31871156	Payment for experimental items, reagents, etc.
	medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China , No. 32171124	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.81672266	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.82072209	Payment for experimental items, reagents, etc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> _None	

3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X _None	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> _None	
8	Patents planned, issued or pending	X _None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X _None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

Form.

### **ICMJE DISCLOSURE FORM**

Date:	Mar 31. 2022	
Your Name:	Liangliang Zheng_	
Manuscript Title	e: Upregulation of FOXO1 co	ntributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>		
Manuscript nun	nber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China , No. 31871156	Payment for experimental items, reagents, etc.
	medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China , No. 32171124	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.81672266	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.82072209	Payment for experimental items, reagents, etc.
		Time frame: past	36 months
2		<b>X</b> _None	

any entity (if not indicated in inter #1 above).  Royalties or licenses  X_None  4 Consulting fees  X_None  5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, pald or unpaid  11 Stock or stock options  X_None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-financial interests		Grants or contracts from		
A Consulting fees  X_None  X_None  A Consulting fees  X_None				
4 Consulting fees		in item #1 above).		
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or nonX_None	3	Royalties or licenses	XNone	
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or nonX_None				
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or nonX_None				
letures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X None   X None  X None  X None  X None	4	Consulting fees	<b>X</b> None	
letures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X None   X None  X None  X None  X None				
letures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X None   X None  X None  X None  X None				
speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- XNone	5		XNone	
manuscript writing or educational events 6  Payment for expert testimony 7  Support for attending meetings and/or travel  8  Patents planned, issued or pending 9  Participation on a Data Safety Monitoring Board or Advisory Board 10  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11  Stock or stock options 12  Receipt of equipment, materials, drugs, medical writing, gifts or other services 13  Other financial or non-    X				
educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Pacecipt of equipment, materials, drugs, medical writing, gifts or other services  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-  May None  May None				
testimony    Support for attending meetings and/or travel				
7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- XNone	6	Payment for expert	<b>X</b> None	
B Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None		testimony		
B Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None				
pending  Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X None XNone	7		<b>X</b> _None	
pending  Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X None XNone				
pending  Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X None XNone				
9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- XNone	8		<b>X</b> _None	
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X_None  X_None		pending		
Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X_None  X_None	_	5 5 .	<b>N</b>	
Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- XNone XNone	9		XNone	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non- XNone				
in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options XNone  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone	10	•	Y None	
committee or advocacy group, paid or unpaid  11 Stock or stock options XNone  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone	10		XNone	
11 Stock or stock options XNone  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone				
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  _X_None  _X_None				
materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone	11	Stock or stock options	XNone	
materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone				
materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone				
writing, gifts or other services  13 Other financial or nonXNone	12		<b>X</b> None	
services  13 Other financial or nonX _None				
		services		
financial interests	13		XNone	
		financial interests		

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:

_X	$_{ t L}$ I certify that I have answered every question and have not altered the wording of any of the questions on this
	form.

Date:	Mar 31. 2022	
Your Name:	Jiankui Du_	
Manuscript Title:	Upregulation of FOX	KO1 contributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>		
Manuscript numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China , No. 31871156	Payment for experimental items, reagents, etc.
	medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China , No. 32171124	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.81672266	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.82072209	Payment for experimental items, reagents, etc.
		Time frame: past	36 months
2		XNone	

	Grants or contracts from any entity (if not indicated in item #1 above).		
3	Royalties or licenses	<b>X</b> _None	
4	Consulting fees	<b>X</b> _None	
_		••	
5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<b>X</b> None	
	testimony		
_			
7	Support for attending	<b>X</b> None	
	meetings and/or travel		
8	Patents planned, issued or	<b>X</b> None	
	pending		
0	Participation on a Data		
9	Participation on a Data Safety Monitoring Board or	<b>X</b> None	
	Advisory Board		
10	Leadership or fiduciary role	<b>X</b> _None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	<b>X</b> None	
12	materials, drugs, medical	<b>X</b> None	
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> _None	
	financial interests		

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:

_X	I certify that I have answered every question and have not altered the wording of any of the questions on this
	form.

Date:	Mar 31. 2022	
Your Name:	Xiaoyan Zhu	
<b>Manuscript Title:</b>	<b>Upregulation of FOX</b>	O1 contributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>		
Manuscript numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China , No. 31871156 National Natural Science Foundation of China , No. 32171124	Payment for experimental items, reagents, etc.  Payment for experimental items, reagents, etc.
	No time illinit for tims item.	National Natural Science Foundation of China , No.81672266 National Natural Science	Payment for experimental items, reagents, etc.  Payment for experimental items, reagents, etc.
		Foundation of China , No.82072209	

	Time frame: past 36 months			
2	Grants or contracts from	XNone		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus, manuscript writing or			
	educational events			
6	Payment for expert	X _None		
	testimony	X_NONC		
	•			
7	Support for attending	XNone		
	meetings and/or travel			
8	Patents planned, issued or	X _None		
	pending			
9	Participation on a Data	X _None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
12	Receipt of equipment,	X _None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### **ICMJE DISCLOSURE FORM**

Date:	Mar 31. 2022_	
Your Name:	Lai Jiang	
<b>Manuscript Title:</b>	Upregulation of	FOXO1 contributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>		
Manuscript numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	National Natural Science Foundation of China , No. 31871156 National Natural Science	Payment for experimental items, reagents, etc.  Payment for experimental items, reagents, etc.
	processing charges, etc.)  No time limit for this item.	Foundation of China , No. 32171124	rayment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.81672266	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.82072209	Payment for experimental items, reagents, etc.

		Time frame: past	36 months
2	Grants or contracts from	<b>X</b> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	<b>X</b> None	
5	Payment or honoraria for	<b>_X</b> _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	<b>X</b> None	
	testimony	XNone	
	,		
7	Support for attending	<b>X</b> _None	
	meetings and/or travel		
8	Patents planned, issued or	<b>X</b> _None	
	pending		
9	Participation on a Data	X _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<b>_X</b> _None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	_X None	
12	Receipt of equipment,	X _None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### **ICMJE DISCLOSURE FORM**

Date:	Mar 31. 2022	
Your Name:	Yujian Liu	
<b>Manuscript Title:</b>	<b>Upregulation of FOXO</b>	1 contributes to LPS-induced pulmonary endothelial injury by induction of
<u>autophagy</u>		
Manuscript numb	er (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	National Natural Science Foundation of China , No. 31871156	Payment for experimental items, reagents, etc.
	medical writing, article processing charges, etc.)  No time limit for this item.	National Natural Science Foundation of China , No. 32171124	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China , No.81672266	Payment for experimental items, reagents, etc.
		National Natural Science Foundation of China ,	Payment for experimental items, reagents, etc.

		No.82072209	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_ <b>X</b> _None	
_	in item #1 above).		
3	Royalties or licenses	X _None	
4	Consulting fees	<b>X</b> _None	
_			
5	Payment or honoraria for lectures, presentations,	<b>X</b> None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	<b>X</b> None	
	testimony		
_			
7	Support for attending meetings and/or travel	<b>X</b> _None	
8	Patents planned, issued or pending	<b>X</b> None	
	pending		
9	Participation on a Data	V None	
9	Safety Monitoring Board or	<b>X</b> _None	
	Advisory Board		
10	Leadership or fiduciary role	_X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical	<b>X</b> None	
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		

The author reports funding from the National Natural Science Foundation of China (No. 31871156, 32171124, 81672266, 82072209).

Please place an "X" next to the following statement to indicate your agreement:		
_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.		